Loading the records…
Loading the records…
S.3607 expands Medicare Part B to cover genetic counseling as a new provider category effective Jan 1, 2027, directly increasing the addressable patient population for genetic testing. This is a structural positive for Labcorp ($LH) and Quest Diagnostics ($DGX) through higher test volume, and for AMN Healthcare ($AMN) through increased demand for scarce genetic counselors. The bill is at early legislative stage (referred to Finance Committee) with companion bill HR6280 in the House.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
For $LH and $DGX, this bill is a medium-term volume catalyst not yet reflected in share prices, which have drifted slightly lower over the past month (-1.49% and -0.11% respectively). Current prices near the midpoints of their 52-week ranges suggest room for upside on legislative progress. For $AMN, which has already risen +12.43% over 30 days, the bill adds further structural support to demand for genetic counselors, though staffing revenue impact is smaller in absolute terms. Investors should watch Senate Finance Committee scheduling and any CMS preliminary fee estimates as catalysts. If the bill gains a committee hearing or markup, expect relative outperformance in these three names versus the broader healthcare market.
S.3607 (Access to Genetic Counselor Services Act of 2026) was introduced on January 8, 2026 by Sen. Barrasso (R-WY) with three cosponsors: Sen. Welch (D-VT), Sen. Capito (R-WV), and Sen. Rosen (D-NV). The bill has been referred to the Senate Committee on Finance. A companion bill, HR6280, exists in the House, referred to the Energy and Commerce and Ways and Means Committees. This bicameral, bipartisan sponsorship signals moderate legislative momentum, but the bill remains in early stages — no hearings or markups have occurred.
The bill does NOT appropriate new funding. It amends the Social Security Act to add genetic counselors as a covered provider type under Medicare Part B, effective January 1, 2027. This is an authorization of coverage, not a spending authorization. The actual spending impact will depend on utilization rates by the ~63 million Medicare beneficiaries. Payment is set at 80% of the lesser of the actual charge or a fee schedule to be determined by CMS. The mechanism is regulatory — it creates a new billing category, which expands the addressable market for downstream diagnostic services.
The structural winners are diagnostic lab companies Labcorp and Quest Diagnostics. Genetic counseling is a gateway service for genetic testing — patients see a counselor, discuss risk factors, and are typically referred for a laboratory test. Currently, Medicare's coverage gap for non-physician genetic counselors creates a bottleneck; this bill removes it. Both LH and DGX have large genetic testing menus (hereditary cancer panels, prenatal screening, pharmacogenomics) that directly benefit from increased counseling-driven orders. AMN Healthcare benefits as the primary pure-play staffing provider for allied health; genetic counselors are a small but high-demand specialty, and Medicare coverage will accelerate hiring.
Examining the provided market data: Over the trailing 30 days (to April 30, 2026), $LH is down -1.49%, $DGX is nearly flat at -0.11%, while $AMN is up +12.43%. Over 7 days, LH and DGX are slightly negative (-0.37% and -0.25% respectively), while AMN gained +1.33%. AMN's strong 30-day performance (+12.43%) may reflect broader healthcare staffing recovery and the bill's introduction in January providing a sentiment lift. The lab stocks are near the middle of their 52-week ranges (LH $235.81-$293.72, current $262.83; DGX $164.65-$213.50, current $195.77), suggesting the bill's early-stage status has not yet been priced in significantly.
The timeline: The bill must pass the Senate Finance Committee, the full Senate, the House, and be signed by the President. With the effective date of January 1, 2027, there is a ~8-month runway from today. Given the 119th Congress runs through January 2027, passage by mid-2026 would allow CMS time to implement fee schedules. A realistic probability of passage is moderate — the bipartisan sponsorship and companion bill are positive signals, but this is not a high-priority leadership bill. If enacted, the impact on lab volumes would be gradual, likely materializing in late 2027 and 2028 as providers build capacity.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
direct reimbursement expansion under Medicare Part B for genetic counseling services, effective Jan 1, 2027
Who must act
Centers for Medicare & Medicaid Services (CMS) and all Medicare Administrative Contractors
What happens
Medicare beneficiaries can now access and bill for genetic counseling services from licensed/certified genetic counselors as a covered benefit, removing a prior barrier where services had to be furnished by or incident to a physician; this expands the addressable patient population for genetic testing orders that typically follow counseling
Stock impact
Labcorp's diagnostics segment, which generates ~$12B+ annual revenue from lab testing including genetic assays, benefits from increased test volume as Medicare patients receiving counseling are more likely to proceed with ordered genetic tests; Labcorp has a leading market position in hereditary cancer and prenatal genetic testing
What the bill does
direct reimbursement expansion under Medicare Part B for genetic counseling services, effective Jan 1, 2027
Who must act
Centers for Medicare & Medicaid Services (CMS) and all Medicare Administrative Contractors
What happens
Same mechanism as for LH: Medicare coverage of genetic counselor services removes a referral bottleneck, increasing the volume of genetic test orders from Medicare beneficiaries; genetic counselors will have a direct incentive to order companion diagnostic tests after counseling sessions
Stock impact
Quest Diagnostics' diagnostic information services segment (~$9B annual revenue) includes a substantial genetic testing portfolio; as the other dominant national lab player alongside Labcorp, Quest captures roughly similar market share in Medicare genetic test volumes; the expanded counseling coverage directly drives test order volume
Matched on shared policy language across AI analyses, with ticker & timing weight
Access to Genetic Counselor Services Act of 2025
Reducing Hereditary Cancer Act
To modernize and strengthen Federal efforts to improve ovarian cancer awareness, hereditary cancer risk assessment, access to genetic counseling and testing, and access to specialty care, and for other purposes.
SAFE Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →